ESI Group at the Farnborough International Airshow 2022
18.7.2022 09:00:00 EEST | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) , a global simulation and virtual prototyping software partner for the industry, will be present at the Farnborough International Airshow (18 and 22 July 2022). ESI Group will present an outline of aircraft Acoustics for both interior and exterior noise. Besides, The Group will illustrate how virtual reality solutions help power industry 4.0, showcasing and demonstrating its solution for human-centric virtual simulation and collaborative work with IC.IDO.
2 software solutions presented:
- ESI’s flagship Virtual Reality software IC.IDO for human-centric process validation and product integration: facilitating agile design processes, robust manufacturing, and safe maintenance operations.
- ESI’s vibro-acoustics software VA ONE for aircraft interiors and electric aircraft like eVTOL concepts: meeting interior noise level comfort and optimizing exterior noise impact in urban areas
Promising progress in the aircraft industry thanks to digitalization and virtual reality
Digitalization plays a major role in developing sustainable aviation, hydrogen planes, electric aircraft, urban mobility, eVTOLs... Virtual reality helps industries achieve sustainability goals, to secure “first time right”, reduce costs, time and go to market. Throughout the years, Virtual reality upgraded processes, allowing faster turnaround for foundries and composite parts manufacturers, lower scrap rates, manufacturability despite new geometries. Industrials have been able to achieve their desired vibro-acoustic performance and virtually pre-certified products. Besides, the need for physical try-outs and prototypes significantly decreased, paving the way to more efficient assembly steps, increased productivity and output, reduced maintenance costs, and decreased industrial risks for operators.
ESI Group has been operating in the aircraft industry for the last decades. ESI’s aerospace customers leverage the benefits of virtual reality solutions, helping them achieve their goal to producing clean, safe, and productive.
eVTOLS: ESI Group helps foster innovations – interior external noise and comfort
ESI has the mission to help aerospace companies in gearing their digital transformation, to be a partner they can trust to help foster innovations, such as the eVTOLS, that will change the landscape of urban mobility. ESI Group is already helping the pioneers of that segment achieve their product performance and safety targets while meeting stringent noise regulations, reducing noise impact in urban areas and meeting interior aircraft noise comfort levels. ESI Group’s VA One software solution help manufacturers to predict and resolve potential noise and vibration challenges in very early stages of their development process. Thus, meeting safety standards and their objectives for aircraft acoustics, and minimizing weight and controlling costs.
ESI Group’s software solutions for a clean, safe, and productive industry
1. Power systems manufacturer Rolls-Royce uses ESI casting simulation software ProCAST for Product-Process co-design and to collaborate more efficiently with their supply chain towards greater quality parts, avoiding late design changes and eliminating scrap rates in a more sustainable manner.
2. Saab Aerospace Systems relies on ESI composites manufacturing simulation software PAM-COMPOSITES to refine their injection strategies for the next generation aircraft doors, supporting the advanced manufacturing of ever lighter structures.
3. Latécoère counts on the advanced virtual reality capabilities provided by IC.IDO (1), to connect manufacturing engineering teams from around the world on the same virtual platform to secure “First Time Right” production and to train operators remotely, cutting down on travel emissions, yet providing a “learning by doing” approach.
(1) ESI Group at the exhibition: France Pavillion. ESI Group will be part of the GIFAS (& “AsTech”) area in HALL 1 – Booth 13.60 Village ASTech
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world, and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220717005031/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Verbatee - Press & Shareholder Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
